[go: up one dir, main page]

IL128851A - Pharmaceutical composition for lowering the uric acid level in the human body - Google Patents

Pharmaceutical composition for lowering the uric acid level in the human body

Info

Publication number
IL128851A
IL128851A IL12885197A IL12885197A IL128851A IL 128851 A IL128851 A IL 128851A IL 12885197 A IL12885197 A IL 12885197A IL 12885197 A IL12885197 A IL 12885197A IL 128851 A IL128851 A IL 128851A
Authority
IL
Israel
Prior art keywords
pct
lowering
uric acid
acid level
pharmaceutical composition
Prior art date
Application number
IL12885197A
Other languages
English (en)
Other versions
IL128851A0 (en
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of IL128851A0 publication Critical patent/IL128851A0/xx
Publication of IL128851A publication Critical patent/IL128851A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
IL12885197A 1996-09-25 1997-09-15 Pharmaceutical composition for lowering the uric acid level in the human body IL128851A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619962.5A GB9619962D0 (en) 1996-09-25 1996-09-25 Medical treatment
PCT/EP1997/005034 WO1998013033A1 (en) 1996-09-25 1997-09-15 Medical treatment

Publications (2)

Publication Number Publication Date
IL128851A0 IL128851A0 (en) 2000-01-31
IL128851A true IL128851A (en) 2001-08-26

Family

ID=10800448

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12885197A IL128851A (en) 1996-09-25 1997-09-15 Pharmaceutical composition for lowering the uric acid level in the human body

Country Status (26)

Country Link
US (1) US6162831A (xx)
EP (1) EP1007023B1 (xx)
JP (1) JP2001501608A (xx)
KR (1) KR20000048568A (xx)
CN (1) CN1231604A (xx)
AT (1) ATE239460T1 (xx)
AU (1) AU722129B2 (xx)
BG (1) BG103278A (xx)
BR (1) BR9711414A (xx)
CA (1) CA2266438A1 (xx)
DE (1) DE69721838T2 (xx)
DK (1) DK1007023T3 (xx)
ES (1) ES2199374T3 (xx)
GB (1) GB9619962D0 (xx)
HR (1) HRP970519A2 (xx)
HU (1) HUP9904545A3 (xx)
IL (1) IL128851A (xx)
NO (1) NO991425D0 (xx)
NZ (1) NZ334668A (xx)
PL (1) PL332423A1 (xx)
PT (1) PT1007023E (xx)
SK (1) SK32199A3 (xx)
TR (1) TR199900649T2 (xx)
TW (1) TW415842B (xx)
WO (1) WO1998013033A1 (xx)
ZA (1) ZA978573B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
CA2366660A1 (en) * 1999-03-19 2000-09-28 Carl M. Mendel Treatment of osteoarthritis
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US9655932B2 (en) * 2002-03-13 2017-05-23 Kibow Biotech, Inc. Composition and method for preventing or treating gout or hyperuricemia
US11103542B2 (en) 2002-03-13 2021-08-31 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
BR0315084A (pt) * 2002-10-05 2005-08-16 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
EP1778261A4 (en) * 2004-07-21 2010-08-11 Univ Florida COMPOSITIONS AND METHODS FOR TREATMENT AND DIAGNOSIS OF INSULIN RESISTANCE
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
US11179426B2 (en) 2016-12-29 2021-11-23 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
EP3906059A4 (en) * 2018-11-02 2022-06-22 Ampersand Biopharmaceuticals, Inc. MANAGING THE RISK OF CATION OVERLOAD AND ELECTROLYTE BALANCE WITH TOPICALLY APPLIED BUFFER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
EP0647134A4 (en) * 1992-06-23 1997-07-30 Sepracor Inc METHODS AND COMPOSITIONS USED TO TREAT DEPRESSION AND OTHER CONDITIONS WITH OPTICALLY PURE SIBUTRAMINE (-).
CA2139000A1 (en) * 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
HRP970519A2 (en) 1998-08-31
AU722129B2 (en) 2000-07-20
TW415842B (en) 2000-12-21
GB9619962D0 (en) 1996-11-13
DE69721838D1 (de) 2003-06-12
JP2001501608A (ja) 2001-02-06
CN1231604A (zh) 1999-10-13
IL128851A0 (en) 2000-01-31
HUP9904545A2 (hu) 2000-11-28
KR20000048568A (ko) 2000-07-25
ATE239460T1 (de) 2003-05-15
PT1007023E (pt) 2003-08-29
AU4385197A (en) 1998-04-17
EP1007023B1 (en) 2003-05-07
NO991425L (no) 1999-03-24
NZ334668A (en) 2000-07-28
HUP9904545A3 (en) 2000-12-28
BG103278A (en) 2000-01-31
PL332423A1 (en) 1999-09-13
EP1007023A1 (en) 2000-06-14
DE69721838T2 (de) 2004-01-22
SK32199A3 (en) 1999-12-10
ZA978573B (en) 1999-03-25
BR9711414A (pt) 2000-04-25
DK1007023T3 (da) 2003-08-25
TR199900649T2 (xx) 1999-07-21
ES2199374T3 (es) 2004-02-16
US6162831A (en) 2000-12-19
NO991425D0 (no) 1999-03-24
CA2266438A1 (en) 1998-04-02
WO1998013033A1 (en) 1998-04-02

Similar Documents

Publication Publication Date Title
IL128851A (en) Pharmaceutical composition for lowering the uric acid level in the human body
PH31220A (en) Medical treatment.
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
CA2367666A1 (en) Method of treating eating disorders
DK1227806T3 (da) Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
IL177626A0 (en) Pharmaceutical compositions for treating sleep apnoea
WO2000056315A8 (en) Treatment of pain
MXPA01009467A (es) Metodo para controlar el aumento de peso asociado con farmacos terapeuticos.
MXPA01009468A (es) Tratamiento de hipertension pulmonar.
BG105999A (en) Treatment of osteoarthritis
BG106000A (en) Treatment of hiatial hernia
EP1234576A4 (en) REMEDIES FOR FOOD DISORDERS
RU99108729A (ru) Способ лечения
BG105995A (en) Weight loss after pregnancy

Legal Events

Date Code Title Description
KB Patent renewed
HCA Change of name of proprietor(s) after amalgamation
RH1 Patent not in force